Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
- 30 May 2022
- journal article
- research article
- Published by Elsevier in Microbial Pathogenesis
- Vol. 168, 105608
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4Cell Research, 2013
- Human viruses: discovery and emergencePhilosophical Transactions of the Royal Society B: Biological Sciences, 2012
- CPY3A4-Mediated Lopinavir Bioactivation and Its Inhibition by RitonavirDrug Metabolism and Disposition, 2012
- Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virusAntiviral Research, 2011
- Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populationsJournal of Antimicrobial Chemotherapy, 2010
- Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with OseltamivirDrug Safety, 2008
- Tamiflu and neuropsychiatric disturbance in adolescentsBMJ, 2007
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802Clinical Pharmacokinetics, 1999
- ZanamivirDrugs, 1999